Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and ...

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Reports Q3 revenue $543.9M, consensus $518.26M. “We continue to achieve significant milestones and robust revenue growth,” said Jim ...

Revenue grew 26% to $543.9 million, ahead of the $519.5 that analysts forecast. Chief Executive Jim Hollingshead said the company's Omnipod 5 automated insulin delivery system -- which was cleared by ...